Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Ambezhu (bevacizumab biosimilar)
i
Other names:
SCT510, SCT 510
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Sinocelltech
Drug class:
VEGF-A inhibitor
Related drugs:
‹
bevacizumab (416)
Aybintio (bevacizumab biosimilar) (14)
bevacizumab-maly (12)
bevacizumab-awwb (11)
bevacizumab-adcd (11)
bevacizumab-tnjn (8)
bevacizumab-bvzr (8)
aflibercept intravitreal (7)
Krabeva (bevacizumab biosimilar) (7)
Byvasda (bevacizumab biosimilar) (4)
ziv-aflibercept IV (4)
BNT327 (2)
CTX-009 (1)
SIBP-04 (bevacizumab biosimilar) (1)
BP102 (bevacizumab biosimilar) (0)
Ankada (bevacizumab biosimilar) (0)
BI 695502 (bevacizumab biosimilar) (0)
MIL 60 (bevacizumab biosimilar) (0)
LY01008 (bevacizumab biosimilar) (0)
CBT124 (bevacizumab biosimilar) (0)
Cizumab (bevacizumab biosimilar) (0)
Equidacent (bevacizumab biosimilar) (0)
GB222 (bevacizumab biosimilar) (0)
GZ402663 (0)
HLX-04 (bevacizumab biosimilar) (0)
LYN-00101 (0)
ranibizumab (0)
MP0250 (0)
MSB0254 (0)
Onbevzi (bevacizumab biosimilar) (0)
PB101 (0)
Pusintin (bevacizumab biosimilar) (0)
TRS003 (bevacizumab biosimilar) (0)
HD204 (bevacizumab biosimilar) (0)
CLS-AX (0)
bevacizumab biosimilar (0)
hVEGF26–104/RFASE (0)
APX003 (0)
bevacizumab (416)
Aybintio (bevacizumab biosimilar) (14)
bevacizumab-maly (12)
bevacizumab-awwb (11)
bevacizumab-adcd (11)
bevacizumab-tnjn (8)
bevacizumab-bvzr (8)
aflibercept intravitreal (7)
Krabeva (bevacizumab biosimilar) (7)
Byvasda (bevacizumab biosimilar) (4)
ziv-aflibercept IV (4)
BNT327 (2)
CTX-009 (1)
SIBP-04 (bevacizumab biosimilar) (1)
BP102 (bevacizumab biosimilar) (0)
Ankada (bevacizumab biosimilar) (0)
BI 695502 (bevacizumab biosimilar) (0)
MIL 60 (bevacizumab biosimilar) (0)
LY01008 (bevacizumab biosimilar) (0)
CBT124 (bevacizumab biosimilar) (0)
Cizumab (bevacizumab biosimilar) (0)
Equidacent (bevacizumab biosimilar) (0)
GB222 (bevacizumab biosimilar) (0)
GZ402663 (0)
HLX-04 (bevacizumab biosimilar) (0)
LYN-00101 (0)
ranibizumab (0)
MP0250 (0)
MSB0254 (0)
Onbevzi (bevacizumab biosimilar) (0)
PB101 (0)
Pusintin (bevacizumab biosimilar) (0)
TRS003 (bevacizumab biosimilar) (0)
HD204 (bevacizumab biosimilar) (0)
CLS-AX (0)
bevacizumab biosimilar (0)
hVEGF26–104/RFASE (0)
APX003 (0)
›
Associations
News
Trials
Filter by
Latest
10ms
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P2/3, N=405, Active, not recruiting, Sinocelltech Ltd. | Recruiting --> Active, not recruiting
10 months ago
Enrollment closed
|
sorafenib • Ambezhu (bevacizumab biosimilar) • finotonlimab (SCT-I10A)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login